Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

NCT01108523 | Terminated Early Phase 1 Results

• 1 other identifier: 828-101-09-017
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates HP828 in the management of moisture associated skin damage after 15 days of use.

Conditions

Skin Abnormalities

Keywords

Moisture Associated Skin Damage

Outcome Measures

Primary Outcomes (1)

• Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15.

  15 Days

Secondary Outcomes (1)

• Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys

  4, 8, 12, and 15 days

Study Arms (1)

HP828-101

EXPERIMENTAL

HP828-101 Experimental Formulation

Device: HP828-101

Interventions

HP828-101 DEVICE

HP828-101

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- The informed consent document must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject or subject representative, and the original signed document placed in the subject's chart. If the subject is unable to read or sign the informed consent, or unable to comprehend the information provided in the consent process, a legal guardian, decision making proxy, or next of kin must provide written consent, and if possible, subject must verbally assent to receiving an experimental treatment for their wound.
• Are 18 years of age or older, of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
• Are expected to remain in the Nursing Home or long-term acute-care (LTAC) for the duration of the study (15 days).
• Have moisture associated skin damage including denuded skin or ulceration, where:
• the damage has been present for at least 2 days but less than 6 weeks
• the area of denudation (target wound) measures greater than or equal to 2 and less than or equal to 64 cm2 in total area
• the area of total damage may be greater than 64 cm2
• Are able to verbally respond to the Pre- and Post- Treatment Survey.
• Women of child-bearing potential may participate in the study if they have a negative urine pregnancy test and use adequate birth control, as determined by the Investigator.
• Are capable of maintaining adequate nutritional intake during the study

You may not qualify if:

• Have more than 64 cm2 of denuded area.
• Have a full-thickness target wound, or a full-thickness wound within 4 cm of any target wound area.
• Have clinical evidence of bacterial or fungal infection of the target wound area.
• Have, within the area of moisture damaged skin, any tunneling, sinus tracks, shear injury, arterial occlusive disease, or bony prominence or joint with the exception that target wounds may be over dorsal spinous processes, coccyx, ischial tuberosities, or sacroiliac joints.
• Are moribund, or have a severe burn, debilitating immunodeficiency disorder, significant hematologic disorder, metastatic malignancy, uncontrolled diabetes mellitus, or any medical conditions that, in the opinion of the Investigator, places the subject at risk for the study or incapable of healing.
• Are known to have acrodermatitis enteropathica (zinc deficiency).
• Are being treated currently with systemic steroids, immunosuppressive agents, radiation, or chemotherapy.
• Have been treated with enzymatic debridement to the target wound area within 2 days prior to enrollment.
• Have a known sensitivity to ingredients of HP828-101.
• Are using or have used another investigational agent (not including devices such as hearing aids, pace makers, etc.) within 30 days prior to Visit 1.
• The Medical Monitor may declare any subject ineligible for a valid medical reason.

Sponsors & Collaborators

• Healthpoint: lead

Study Sites (1)

Golden Acres

Dallas, Texas, 75228, United States

Location

MeSH Terms

Conditions

Skin Abnormalities

Condition Hierarchy (Ancestors)

Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Jaime Dickerson, PhD
• Organization: Smith & Nephew Biotherapeutics

jaime.dickerson@smith-nephew.com

817-302-3914

Study Officials

• Herbert B Slade, MD

  Healthpoint

  STUDY CHAIR

• Neeta Nayak, MD

  Golden Acres

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 20, 2010
• First Posted: April 22, 2010
• Study Start: April 1, 2010
• Primary Completion: July 1, 2010
• Study Completion: February 1, 2012
• Last Updated: December 6, 2013
• Results First Posted: December 6, 2013

Record last verified: 2013-10

Locations

US (1)